Portal de investigação
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Tromp J.
- Kosiborod M.N.
- Angermann C.E.
- Collins S.P.
- Teerlink J.R.
- Ponikowski P.
- Biegus J.
- Nassif M.E.
- Psotka M.A.
- Brueckmann M.
- Blatchford J.P.
- Steubl D.
- Voors A.A.
Unidades de investigação
Abstract
Aim: The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF). Methods and results: A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF. For the present analysis, patients were classified as HF with reduced (HFrEF, LVEF =40%), mildly reduced (HFmrEF, LVEF 41–49%) or preserved (HFpEF, LVEF =50%) ejection fraction at baseline. The primary endpoint was a hierarchical outcome of death, worsening HF events (HFE) and quality of life over 90 days, assessed by the win ratio. Secondary endpoints included individual components of the primary endpoint and safety. Out of 523 patients with baseline data, 354 (67.7%) had HFrEF, 54 (10.3%) had HFmrEF and 115 (22.0%) had HFpEF. The clinical benefit (hierarchical composite of all-cause death, HFE and Kansas City Cardiomyopathy Questionnaire total symptom score) of empagliflozin at 90 days compared to placebo was consistent across LVEF categories (=40%: win ratio 1.35 [95% confidence interval 1.04, 1.75]; 41–49%: win ratio 1.25 [0.66, 2.37)] and =50%: win ratio 1.40 [0.87, 2.23], pinteraction = 0.96) with a favourable safety profile. Results were consistent across individual components of the hierarchical primary endpoint. Conclusion: The clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial. These results support early in-hospital initiation of empagliflozin regardless of LVEF. © 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Dados da publicação
- ISSN/ISSNe:
- 1388-9842, 1879-0844
- Tipo:
- Article
- Páginas:
- 963-970
- DOI:
- 10.1002/ejhf.3218
- Link para outro recurso:
- www.scopus.com
European Journal of Heart Failure Wiley-Blackwell
Citações Recebidas na Scopus: 6
Documentos
- Não há documentos
Filiações
Keywords
- Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left; empagliflozin; furosemide; hemoglobin; benzhydryl derivative; empagliflozin; glucoside; sodium glucose cotransporter 2 inhibitor; acute heart failure; acute kidney failure; adult; aged; Article; atrial fibrillation; clinical outcome; controlled study; coronary artery bypass graft; diabetes mellitus; diastolic blood pressure; double blind procedure; dyspnea; female; glomerulus filtration rate; heart failure; heart left ventricle ejection fraction; human; hypotension; major clinical study; male; multicenter study; non insulin dependent diabetes mellitus; randomized controlled trial; systolic blood pressure; urinary tract infection; clinical trial; drug effect; drug therapy; heart failure; heart left ventricle function; heart stroke volume; hosp
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Tromp J,Kosiborod MN,Angermann CE,Collins SP,Teerlink JR,Ponikowski P,Biegus J,Ferreira JP,Nassif ME,Psotka MA,Brueckmann M,Blatchford JP,Steubl D,Voors AA. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial. Eur. J. Heart Fail. 2024. 26. (4):p. 963-970. IF:18,200. (1).
